Gene Garrard Olinger, PhD, MBA
Adjunct Associate Professor
Boston University School of Medicine
Dept of Medicine
Infectious Diseases

PhD, Rush University
MBA, Mount St. Mary's University
Websites
favorite icon Linkedin




Gene Garrard Olinger, Jr. received his Ph.D. from Rush University Medical Center in Chicago, IL in 2001. Currently, Dr. Olinger is the principal advisor science for MRI Global Inc.

Dr. Olinger holds a Masters in Business Administration from Mount Saint Mary’s University in Emmittsburg, MD, has completed executive training at Massachusetts Institute of Technology, Boston, MA, and completed Department of Defense Acquisition and Executive Leadership training. He is the recipient of the Achievement Medal for Civilian Service Medals in 2005 and 2010, Commander’s Award for Civilian Service in 2013, and the NIH Director Award in 2015 for his efforts assisting with the Ebola outbreak in Western Africa. Dr. Olinger is active in multiple STEM programs and mentors high school, undergraduate graduate students and post-doctoral fellows.

Associate Director for Maximum Containment Training, NEIDL
Boston University School of Medicine
National Emerging Infectious Disease Lab


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Postnikova E, Cong Y, DeWald LE, Dyall J, Yu S, Hart BJ, Zhou H, Gross R, Logue J, Cai Y, Deiuliis N, Michelotti J, Honko AN, Bennett RS, Holbrook MR, Olinger GG, Hensley LE, Jahrling PB. Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. PLoS One. 2018; 13(3):e0194880. PMID: 29566079.
     
  2. Logue J, Tuznik K, Follmann D, Grandits G, Marchand J, Reilly C, Sarro YDS, Pettitt J, Stavale EJ, Fallah M, Olinger GG, Bolay FK, Hensley LE. Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay. J Virol Methods. 2018 05; 255:84-90. PMID: 29481881.
     
  3. Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger GG, Hensley LE, Frieman MB, Jahrling PB. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. Drugs. 2017 Dec; 77(18):1935-1966. PMID: 29143192.
     
  4. Honko AN, Johnson JC, Marchand JS, Huzella L, Adams RD, Oberlander N, Torzewski LM, Bennett RS, Hensley LE, Jahrling PB, Olinger GG. High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona. Sci Rep. 2017 Jul 19; 7(1):5886. PMID: 28725019.
     
  5. Lennemann NJ, Herbert AS, Brouillette R, Rhein B, Bakken RA, Perschbacher KJ, Cooney AL, Miller-Hunt CL, Ten Eyck P, Biggins J, Olinger G, Dye JM, Maury W. Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice. J Virol. 2017 Jun 14. PMID: 28615211.
     
  6. Dyall J, Hart BJ, Postnikova E, Cong Y, Zhou H, Gerhardt DM, Freeburger D, Michelotti J, Honko AN, DeWald LE, Bennett RS, Olinger GG, Jahrling PB, Hensley LE. Interferon-ß and Interferon-? Are Weak Inhibitors of Ebola Virus in Cell-Based Assays. J Infect Dis. 2017 May 01; 215(9):1416-1420. PMID: 28368541; DOI: 10.1093/infdis/jix134;.
     
  7. Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, Michelotti J, Dewey WH, DeWald LE, Bennett RS, Morris PJ, Guha R, Klumpp-Thomas C, McKnight C, Chen YC, Xu X, Wang A, Hughes E, Martin S, Thomas C, Jahrling PB, Hensley LE, Olinger GG, White JM. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. PLoS Negl Trop Dis. 2017 Apr; 11(4):e0005540. PMID: 28403145; DOI: 10.1371/journal.pntd.0005540;.
     
  8. Bennett RS, Huzella LM, Jahrling PB, Bollinger L, Olinger GG, Hensley LE. Nonhuman Primate Models of Ebola Virus Disease. Curr Top Microbiol Immunol. 2017; 411:171-193. PMID: 28643203.
     
  9. Connor J, Kobinger G, Olinger G. Therapeutics Against Filovirus Infection. Curr Top Microbiol Immunol. 2017; 411:263-290.View Related Profiles. PMID: 28653190.
     
  10. Cong Y, Dyall J, Hart BJ, DeWald LE, Johnson JC, Postnikova E, Zhou H, Gross R, Rojas O, Alexander I, Josleyn N, Zhang T, Michelotti J, Janosko K, Glass PJ, Flint M, McMullan LK, Spiropoulou CF, Mierzwa T, Guha R, Shinn P, Michael S, Klumpp-Thomas C, McKnight C, Thomas C, Eakin AE, O'Loughlin KG, Green CE, Catz P, Mirsalis JC, Honko AN, Olinger GG, Bennett RS, Holbrook MR, Hensley LE, Jahrling PB. Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus. PLoS One. 2016; 11(11):e0166318. PMID: 27902714; DOI: 10.1371/journal.pone.0166318;.
     
Showing 10 of 80 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 80 publications over 18 distinct years, with a maximum of 13 publications in 2015

YearPublications
19993
20001
20012
20021
20053
20063
20074
20081
20094
20102
20115
20126
201311
20148
201513
20164
20177
20182
Contact for Mentoring:


620 Albany St
Boston MA 02118
Google Map


Olinger's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department